Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.48%. At the same time, ...

The biotech is entering a new era.

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort ...

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged ...

Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized ...

CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and ...

Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped ...

After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of ...

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing skin cancer from returning or spreading in a study of melanoma patients.

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.